Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

extended-release

extended-release is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 16
Pipeline programs 38
News articles 0
Drug details — extended-release
Class
—
Route
—
Patents
16
Programs
38
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

extended-release is an FDA-listed pharmaceutical active ingredient.

Key facts

INN extended-release

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Aceneuramic Acid Extended-Release Tablets Phase 3 · Ultragenyx UK · Hereditary Inclusion Body Myopathy
  2. Delayed and extended release mesalazine Phase 3 · Takeda · Colitis, Ulcerative
  3. Extended Release Buprenorphine Phase 3 · BRIGHT MINDS BIOSCIENCES · Substance Use Disorder
  4. Extended Release Naltrexone Phase 3 · BRIGHT MINDS BIOSCIENCES · Opioid Use Disorder
  5. Extended-release Guanfacine Hydrochloride Phase 3 · Takeda · Attention-deficit/Hyperactivity Disorder
  6. Pramipexol Extended Release Phase 3 · Boehringer Ingelheim · Early Parkinson Disease (Early PD)
  7. ROR-PH-301 Phase 3 · United Therapeutics Europe · Pulmonary arterial hypertension (PAH)
  8. Rosiglitazone Extended Release 2mg Phase 3 · GSK Glaxo Smith · Alzheimer's Disease

Related patents

Browse patents

  1. US 12233166

    Extended release compositions comprising pyridostigmine

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11911515

    Extended release compositions comprising pyridostigmine

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11672762

    Onapristone extended-release compositions and methods

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11666536

    Extended release compositions comprising pyridostigmine

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11564888

    Extended release compositions comprising trihexyphenidyl

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11478430

    Implantable medical devices for extended release of therapeutic agents

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11478425

    Extended release compositions comprising pyridostigmine

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11229606

    Extended release compositions comprising pyridostigmine

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10786461

    Onapristone extended-release compositions and methods

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10688056

    Implantable medical devices for extended release of therapeutic agents

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10045943

    Implantable medical devices for extended release of therapeutic agents

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9636305

    Antiemetic extended release solid dosage forms

    Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 2016051546

    CRYSTALLIZATION PROCESS OF ARIPIPRAZOLE DERIVATIVES IN EXTENDED RELEASE FORMULATIONS FOR TREATMENT OF SCHIZOPHRENIA

    Expires Wed Feb 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9125833

    Multimodal abuse resistant and extended release opioid formulations

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8409616

    Extended release opioid abuse deterrent compositions and methods of making same

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8101630

    Extended release opioid abuse deterrent compositions and methods of making same

    Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is extended-release?

extended-release is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.